Related Experiment Video
Updated: Jun 20, 2026

Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload
Published on: March 14, 2017
Neurocognitive Impairment in Ugandan Children with Sickle Cell Anemia Compared to Sibling Controls: A cross-sectional
Paul Bangirana1,2, Amelia K Boehme3, Annet Birabwa4
1Department of Psychiatry, Makerere University College of Health Sciences, Kampala, Uganda.
Insights
Children with sickle cell anemia (SCA) older than age 4 show impaired neurocognitive function compared to siblings. Prior stroke and disease severity are key risk factors for cognitive deficits in SCA.
Area of Science:
- Pediatric Neurology
- Hematology
- Neuroscience
Background:
- Sickle cell anemia (SCA) is a genetic blood disorder that can affect neurocognitive development in children.
- Identifying risk factors for cognitive impairment in children with SCA is crucial for timely intervention.
Approach:
- A cross-sectional study compared neurocognitive function in 242 Ugandan children with SCA to 127 non-SCA siblings using standardized cognitive, executive function, and attention tests.
- Neurocognitive scores were converted to age-normalized z-scores, and SCA patients underwent stroke assessment and transcranial Doppler ultrasound.
Key Points:
- Children with SCA demonstrated significantly lower overall cognitive and executive function z-scores compared to their siblings.
- Neurocognitive deficits in SCA were more pronounced in children older than 4 years.
- Prior stroke, disease severity, and age were identified as the strongest predictors of poor neurocognitive outcomes in children with SCA.
Conclusions:
- Children with SCA, particularly those over age 4, exhibit poorer neurocognitive functioning.
- The findings highlight the need for clinical trials to evaluate disease-modifying therapies for improving neurocognitive outcomes in pediatric SCA.
Introduction:
Neurocognitive function in Ugandan children aged 1-12 years with sickle cell anemia (SCA) were compared to their non-SCA siblings to identify risk factors for disease-associated impairment.
Methods:
This cross-sectional neurocognitive function study of children with SCA (N=242) and non-SCA siblings (N=127) used age- and linguistically-appropriate standardized tests of cognition, executive function and attention for children ages 1-4 and 5-12 years. Test scores were converted to locally derived age-normalized z-scores. The SCA group underwent standardized stroke examination for prior stroke and transcranial doppler ultrasound (TCD) to determine stroke risk by arterial flow velocity.
Results:
The SCA group was younger than siblings (mean ages 5.46±3.0 versus 7.11±3.51 years, respectively; p <.001), with lower hemoglobin concentration (7.32±1.02 vs. 12.06±1.42, p <.001). Overall cognitive SCA z-scores were lower: -0.73 ±0.98 vs. siblings -0.25 ±1.12 (p<.001), with comparable findings for executive function of -1.09±0.94 versus -0.84±1.26 (p=0.045), respectively. Attention z-scores for ages 5-12 for the SCA group and controls were similar: -0.37±1.4 vs. -0.11±0.17 (p=.09). Overall differences by SCA status were largely driven by the older age group, as z-scores in the younger sub-sample did not differ from controls. Analyses revealed the strongest predictors of poor neurocognitive outcomes among the SCA sample to be the disease, age and prior stroke (each p<.001). Impact from anemia and SCA were indistinguishable.
Discussion:
Neurocognitive testing in children with SCA compared to non-SCA siblings revealed poorer SCA-associated functioning in children older than age 4. Results indicate need for trials assessing impact from disease modification for children with SCA.
More Related Videos
Related Concept Videos
Photoreceptors and Visual Pathways
Prosopagnosia
Learning Disabilities
Dyslexia
Dyslexia is a...
Relationship with Other Adult Family Members and Siblings
Diabetic Retinopathy

